Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: kinase inhibitors - Exelixis

Next Previous
X
Search
Drug Profile

Research programme: kinase inhibitors - Exelixis

Alternative Names: EXEL 0862; EXEL 2280; EXEL 2819; EXEL 2942; EXEL 6309; EXEL-8232; mTORC1/mTORC2 inhibitor (XL388); XL 388

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exelixis
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Aurora kinase A inhibitors; Insulin-like growth factor I inhibitors; Janus kinase 2 inhibitors; Mitogen-activated protein kinase kinase inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors; Phosphoric monoester hydrolase inhibitors; Phosphotransferase inhibitors; Proto-oncogene protein c-akt inhibitors; Proto-oncogene protein c-kit inhibitors; Raf kinase inhibitors; Src-family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer; Myeloproliferative disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Myeloproliferative disorders in USA (PO)
  • 19 Nov 2009 Pharmacodynamics data from preclinical trials in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009) ,

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top